Call Us: 1 (800) 647 6100

6900 Kingspointe Pkwy, Orlando, FL 32819, US

Open in Google Maps


6900 Kingspointe Pkwy, Orlando, FL 32819, US

Open in Google Maps

People-First Culture

XYMOGEN thrives on its culture of strong customer service, personal excellence, high energy, and the true enjoyment of helping people improve their health.

People-First Culture

About Us

When you partner with XYMOGEN, you not only receive the-highest quality formulas in the practitioner channel; you also get the support of our long-standing functional medicine consultant team, as well as the best customer service in the industry. Why? Simple: Because we care. We care about the fact that you want to help people live their healthiest. We care that you want safe, effective formulas on which you can rely. We are a team, helping to bring patients what they are searching for — better health and wellness.


The Journey Is the Reward
XYMOGEN Exclusive Professional Formulas has over a quarter century of experience providing quality supplements to healthcare practitioners. As an independent health sciences company, XYMOGEN has introduced numerous innovations to the functional medicine community. From the beginning, "the journey is the reward" has been our mantra. It is a journey that offers unprecedented opportunities for growth and fulfillment.


XYMOGEN’s Core Principle: People-First 

XYMOGEN is proud of our "People-First" culture. We can only achieve continued success and growth by staying tenaciously committed to these five principles:

  • Creating a dynamic, open corporate environment that encourages a team approach to problem solving, new product development and industry first initiatives.
  • Establishing an inverted pyramid organizational structure where the first priority of all leaders is to ensure every team member knows that their thoughts and opinions are encouraged and valued.
  • Providing resources, education and training for team members to maximize their highest potential so that they may move up in our company and find career satisfaction.
  • Encouraging fitness, health and to make time for play by offering team members access to our 24/7, no-fee exercise facilities, which includes a basketball/volleyball court as well as a fitness center with treadmills and weights.
  • Attracting the most talented, fun and motivated people from many different backgrounds to our winning team through a variety of avenues, including relationship building with the scores of professionals who have maximized their health through our formulas and our already established team of diverse and deeply devoted team members.



In October of 2003, the nutraceutical company XYMOGEN was created. Since that time, XYMOGEN has shown considerable growth with more than a decade of continued success. The company has repeatedly outgrown offices, necessitating the construction in 2012 of a new, state-of-the-art manufacturing facility. It has also developed its own lucrative private labeling program, launched the subsidiary company Labels in Motion, and gone from a distributorship to a supplement manufacturer. Here’s to the future, with even more success to come.

Passion + Commitment = Growth
Our commitment to quality, our commitment to our practitioners, and a passion for natural healthcare allow us to keep growing. Our team mentality, quarterly product pipeline launches, continuing education events, customer recognition programs, and international expansion also contribute to our continued ability to rise above the competition. XYMOGEN’s strength as a company has been reinforced repeatedly. XYMOGEN has recently been recognized for the ninth time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best-run private companies in the nation.  XYMOGEN joined the “Honor Roll Alumni” in 2012, which is the elite group of companies who have made the list at least five times. They have now appeared nine times in the last ten years, putting them among only five percent of the current 5000 honorees to be featured nine or more times.

Partnership with Dr. David Perlmutter, FACN, ABIHM
In February 2010, XYMOGEN acquired Dr. David Perlmutter’s iNutritionals line of neurological formulas. The addition of BrainSustain™ and NeuroActives™ BrainSustain™ to the XYMOGEN line positions us as a leader in the modulation of neurological disorders.

XYMOGEN Facility

XYMOGEN proved that there really is no place like home as we opened our new global headquarters in Orlando, FL, in April 2012. The complex’s design strategically weaves an ultramodern manufacturing and packaging system, a merchandise center, full-service research laboratories, a warehouse, marketing studios, a customer service department, digital printing services, and administrative services under one massive roof.

More than 40,000 square feet are dedicated to manufacturing and packaging, and this also includes a 4,000-square-foot full-service laboratory to test all raw materials and goods.

The expanding success of XYMOGEN’s seminar series and tradeshow exhibitions motivated us to include our own conference center in the building. This enables us to host educational programs in the facility year-round.

Our new headquarters was built to LEED (Leadership in Energy and Environmental Design) standards. For a start, it offers “green” features, such as parking spaces dedicated to energy-efficient cars, and there is a non-smoking policy.

From day one, founder Brian Blackburn’s business has been structured around core family values, and a happy and positive workplace. For that reason, the building design also includes spacious work areas, a 24-hour gymnasium, and a basketball court for the more than 150 employees.

The XYMOGEN work environment has always been Brian Blackburn’s first priority. He believes that the successful operation of a business pivots on nurturing and caring for employees. This philosophy continues today.


Generating Higher Value

Q4 2004 - $7.50

Q4 2005 - $12.50

Q4 2006 - $12.50

Q4 2007 - $15.00

Q4 2008 - $23.65

Q4 2009 - $34.12

Q4 2010 - $45.70

Q4 2011 - $56.51

Q4 2012 - $60.54

Q4 2013 - $75.62

Q4 2014 - $83.61

Q4 2015 - $96.54

Q4 2016 - $110.34

Q4 2017 - $126.84

Q4 2018 - $152.28

Q4 2019 - $149.30

Q4 2020 - $158.62

Q4 2021 - $172.92

Q1 2022 - $173.12

Q4 2022 - $176.94

Q2 2022 - $176.94

Dear XYMOGEN Partner,

XYMOGEN's growth and success are a testament to the people, philosophy and culture that continue to make this journey we call XYMOGEN so exciting. We are committed long-term to all team members, customers and investors who have contributed and continue to contribute to our success.

What distinguishes XYMOGEN from other nutraceutical companies is our creativity. We are a very creative organization, and we strive to use our creativity in everything we do. I believe that the best way to predict the future is to create it, and our creativity helps us stay ahead of the competition and remain the premier source of nutritional products in the practitioner channel.

When XYMOGEN was launched in 2003, we understood that to maintain our commitments of exclusivity to our practitioners and opportunity to our team members, we needed to invest in innovation and technology. To that end, a phenomenon has been evolving at XYMOGEN since 2019 called the Tipping Point, which occurs after a decision to challenge the status quo and take on the enormous challenge of REINVENTING an organization. Over the past three years, all members of our team dedicated countless hours and overcame many hurdles to successfully launch the disruptive innovations listed below. We have REINVENTED XYMOGEN and are now beginning to see the fruits of our labor. Increased sales and efficiencies will pave the way for growth. In April 2022, we celebrated a major step in our status quo journey – the 10-year anniversary of our 137,000 sq. ft. state-of-the-art manufacturing headquarters in Orlando, which has since expanded to a 309,000 sq. ft. campus.

As a result of our creative efforts, we have seen overwhelming success in our international expansion and also with our digital printing company, XYMOPrint. We also plan to introduce and expand numerous innovations in the coming year, including Private Label NOW, our streamlined labeling and warehousing program, and our science-based approach to personalized nutrition that allows practitioners and patients to create unique, daily supplement packets, designed to replace the patients' many formula bottles, in addition to numerous other additions and revisions to enhance our formula line.

Naturally, XYMOGEN aims to serve our customers' health needs, but we are also dedicated to helping the environment. Our continued partnership with the United Nations CleanSeas initiative means we are always looking for ways to decrease our use of plastic. The single-serve packet machine is one way we hope to accomplish this. Replacing high-density polyethylene (HDPE) rigid plastic tubs with thin-film dose packs packaged in paper cartons will help XYMOGEN use approximately 40% less plastic in its packaging. Keeping in line with plastic reduction, the new Condition-Specific formulas in convenient, on-the-go packets have received a great deal of interest from practitioners for innovation and increased patient compliance.

On behalf of our ever growing XYMOGEN TEAM, I wish you all the best for a healthy, happy and prosperous journey with us.


Brian J. Blackburn, CEO


Company Overview

Functional medicine is the future of preventative health care and the cornerstone of XYMOGEN. It is a personalized, body systems-based approach that allows healthcare practitioners and patients to work in collaboration and address the underlying causes of disease. XYMOGEN's mission is building relationships that empower practitioners to help their patients reach their highest expression of health through the use of exclusive functional medicine formulas.

XYMOGEN® is family-owned health sciences company headquartered in Orlando, Florida and has been providing high-quality dietary supplements to licensed health care practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who are industry experts in a broad range of specialties.


Certified Manufacturing Facility

XYMOGEN's 308,000-square-foot manufacturing facility is GMP (good manufacturing practices) registered by NSF International. The NSF mark assures consumers, retailers, and regulators that products have been rigorously tested to comply with all standard requirements.


Fastest Growing

XYMOGEN is a family-owned health sciences company headquartered in Orlando, Fla., which has been manufacturing and distributing high-quality dietary supplements, and providing education and support to licensed healthcare practitioners for more than a quarter century. Guided by XYMOGEN's founding principles of quality, trust, and service, XYMOGEN launched WholeScripts, the only one-stop ordering site for exclusive XYMOGEN formulas and other professional-grade supplements. The mission of WholeScripts is to be a digital dispensary of choice as well as an integrative medicine tool that supports the entire healthcare community. XYMOGEN's 309,000-square-foot campus includes sister companies WholeScripts, WholeScripts Pharmacy, XYMOPrint, a state-of-the-art digital printing, label, and packaging solutions company; XYMOGEN Logistics, a superiorly managed, climate-controlled warehouse with full security and fire protection; XYMOGYM, a full-service gym, which also includes our corporate health and wellness program, XYMOFIT, strongly focusing on the Institute of Functional Medicine’s five pillars of health, as well as PharmaceutiX, a medical food distribution company.

XYMOGEN is fortunate to be in the Practitioner Channel of the Health & Wellness Sector. Over the past five years, this has been among the fastest-growing business sectors in our country. At a time when few companies are growing, as of June 30, 2022, XYMOGEN has grown revenues for 70 quarters and has realized over 100 percent growth in the past five years. Over this five-year period the share price has grown from $115.43 to $176.94. We believe with our current and planned initiatives the next two years will likely be our best growth period to date.


Quarterly Share Price


XYMOGEN's share price is valued quarterly, and, as of June 30, 2022, the share price is posted to our website with a value of $176.94 per share. The next share valuation, as of September 30, 2022, will be posted to our website on or about October 28, 2022.



  • WholeScripts™:  An expanded digital interface for practitioners and patients that will replace the XYMOGEN eStore and offer a more intuitive and robust user experience. WholeScripts will be dedicated to providing access to exclusive XYMOGEN formulas, with other professional-grade nutritional and herbal supplements coming on line later down the road, so that WholeScripts is a one-stop nutraceutical dispensary for quality formulas.
    Here are just a few of the ways WholeScripts will be the choice of savvy healthcare practitioners and a benefit to their patients:
    • Exclusivity
      XYMOGEN is not sold through third-party retailers such as Amazon or other online retailers. This keeps the integrity of the formulas intact and ensures practitioners that their patients are getting the right formulas at the right potency each and every time. WholeScripts is the ONLY site authorized to sell XYMOGEN formulas direct to patients with a referring practitioner.
    • Electronic medical record/electronic health record (EMR/EHR) integration
      WholeScripts has partnered with Cerbo (formerly MDHQ), a leading EMR/EHR to put patient information at practitioners' fingertips. No more time-consuming data entry from one system to another. Practitioners will be able to import XYMOGEN formulas, create recommendations, and view patient compliance at the click of a button. More software integrations are expected soon.
    • Smart inventory management is not managing inventory at all
      As a busy practitioner, there is little time or space to keep a fully-stocked natural pharmacy. Let us take care of the inventory for you. With WholeScripts, save space, time and costs – without ever having to worry about expiration dates on formulas.
    • Improved user experience
      The new website is focused on a design that is easily viewable on mobile devices with a quicker checkout process, better catalog searching capabilities and more filtering choices. Likewise, an adjustment to AutoShip will allow re-orders by formula rather than an entire order, ensuring patients always have their supplements on hand.
    • Free shipping for patients
      A patients' best friend is free shipping. WholeScripts will offer free shipping for all patient orders of $49 or more. What's more there are absolutely no patient subscription fees and AutoShip can be stopped and started at any time by patients.
  • CleanSeas: XYMOGEN is one of the first corporations to pledge its support to the United Nations Environment Programme (UNEP) CleanSeas initiative, and is the only nutraceutical company to do so. CleanSeas, which was launched in February of 2017, aims to target the causes of marine litter by limiting the production and consumption of non-recoverable and single-use plastic such as bottles, bags, and straws. The initiative encourages government, corporate, and community involvement to achieve this goal. To this end, XYMOGEN is curtailing its use of plastics by moving from plastic bottles to thin-film dose packs, which are packaged in paper cartons. The same is true for its large, plastic tubs that contain powders, such as the FIT Food and OptiCleanse family of formulas. In place of these, patients may choose to receive their formulas in perfectly portioned thin-plastic serving packets, which also use considerably less plastic.
  • Quarterly Pipeline Launches: XYMOGEN's continued growth and success allows us to keep expanding and improving our line of formulas in order to meet patients' health needs. Our quarterly releases of innovative formulas reflect the latest scientific findings in the field of nutritional science as well as feedback from our Medical Board of Advisors and XYMOGEN practitioners worldwide.
  • International Growth: XYMOGEN continues to see new opportunities to address the ever-expanding need for natural health solutions by distributing its top-of-the-line formulas across the global market. The goal is to ensure XYMOGEN products are supplied to every distributor that recognizes the benefits of providing these innovative formulas to consumers, and has a desire to help people achieve a healthier lifestyle. XYMOGEN is currently distributing in Canada (where XYMOGEN maintains its own sales force and fulfillment center), South Korea, South Africa, China, Taiwan, Singapore, Australia, New Zealand, Mexico, Indonesia, Peru, Ecuador, Vietnam, and Ukraine – and is looking to develop markets in Iran, Saudi Arabia, Pakistan and throughout Europe. These future ventures can only be realized through strong partnerships with potential distributors who share XYMOGEN's vision.
  • ePedigree Verification: XYMOGEN provides products only to licensed healthcare practitioners and their authorized patients. Products sold through discount Internet websites are strictly prohibited. These suppliers are not approved distributors, and XYMOGEN cannot guarantee the authenticity, potency or efficacy of products purchased through such sites. The main goal of our ePedigree initiative is to protect consumers from receiving unauthentic XYMOGEN products from unauthorized Internet sources by creating an electronic record which tracks our products as they move from the manufacturing floor to the customer. With ePedigree, we are eliminating all Internet sales of XYMOGEN-labeled formulas, resulting in XYMOGEN being the only truly exclusive source of proprietary supplements in the practitioner channel.
  • Personalized Medicine: XYMOGEN's exclusive, professional formulas are precisely calculated to restore nutritional depletions based on the patient's unique lifestyle, diet or drug therapies, and timed to support optimum effectiveness. Beginning with a thorough evaluation of a patient's medical history, our proprietary system develops a detailed, individualized report from which formula recommendations are derived, and then combines the formulas into convenient AM/PM dose packs for a personal nutritional supplement kit. With our three-step approach – exact formula, exact dosing, and exact timing – we take the guesswork out of choosing and using dietary supplements to support the goal of optimal health.
  • PharmaceutiX® Medical Foods: The rising demand for natural health products has created great potential to introduce new formulas onto the market. As a company that is looking to grow and expand, the possibilities for XYMOGEN are endless, as we strive to develop formulas that can help an even larger base of the patient population. Medical foods are defined by the FDA as foods specifically formulated to provide nutrients for the management of a disease for which there is a recognized nutrient dysfunction or deficiency component. Medical foods must be used under the care and oversight of a physician, and they must meet the FDA's rigorous safety requirements.
  • Private Label Program: Using this powerful tool, doctors and practitioners everywhere are seeing results, attributed to having personal and customized labels, doctor reference sheets and booklets for their favorite XYMOGEN formulas.
  • Custom Manufacturing: This option allows our customers to develop their own formulas, including ingredients and amounts, while XYMOGEN seeks out the very best raw materials and offers a choice of delivery methods, coating, packaging and labeling. These formulas are manufactured in XYMOGEN's state-of-the-art facility to ensure the customer's creation is exactly as they imagined it, if not better.
  • Contract Manufacturing: Based on the extraordinary growth of both XYMOGEN's infrastructure and team, we are now well-positioned to fulfill orders in Contract Manufacturing, our fastest growth division. XYMOGEN has also received commitments from three of its European Biotech partners to become the exclusive manufacturer for a series of patented and proprietary ingredients.
  • XYMOPrint™: An expert in the creation of digital print products. Providing label and print services for XYMOGEN®, WholeScripts™ Pharmacy, PharmaceutiX®, private label, and custom and contract manufacturing customers, XYMOPrint also partners with brands and industries around the world to design and manufacture labels with an unbeatable quality and value.


Financial Outlook

XYMOGEN Posts Revenues of $32.491 Million for Q2 2022

XYMOGEN’s net sales for Q2 2022 increased 3.1% to $32,490,857 compared to the $31,520,734 generated during the same quarter last year. Sales for the first six months of 2022 were 2.4% higher at $65,193,556 than the last year total of $63,653,728. EBITDA dropped to $4.61 million for the first half of this year compared to the $5.51 million posted through June 2021. We expect the next two quarters of sales and EBITDA numbers to exceed those from last year.

XYMOGEN sales increased 6.4% to $128.43 million in 2021 up from the $120.67 million posted last year. These numbers follow 14 straight years of double-digit revenue gains reached prior to 2019. The XYMOGEN management team identified numerous growth opportunities a couple of years ago and secured a lease on the 172,000 sq. ft. warehouse next door to its 137,000 sq. ft. headquarters in Orlando, FL. Our CEO, Brian Blackburn Sr., then presented his seven-year growth plan, the “Road to $500 Million”. Several of the steps necessary to facilitate this plan such as customizing the new space next door for the operations that needed to move over there, expanding our manufacturing capabilities in our headquarter building, including various new pieces of high-speed equipment and upgrading to the much more powerful SAP software that could handle this growth, have already been implemented. Much of this was accomplished from 2019-2021 with investments exceeding $20 million. That led to anticipated disruptions in our business resulting in a temporary drop in net sales in 2019 and slower-than-projected growth in 2020 and 2021, which was also adversely affected by the pandemic.

The Management Team continues to be excited and has high expectations for 2022-2023 and beyond. We will invest additional millions of dollars throughout 2022 to continue this ‘REINVENTION of XYMOGEN’ that represents a profound transformation of our company, and we fully expect it will have a very positive impact on your investment. To recap, we have vertically integrated and added wholly owned divisions including:

  • WholeScripts, LLC – our e-commerce distribution company that fulfills all XYMOGEN formulas and will continue to maintain up to 99 of our customers’ most requested non-XYMOGEN brands.
  • XYMOGEN Manufacturing, LLC – our manufacturing division for XYMOGEN-brand and third-party custom formulas.
  • XYMOPrint, LLC – our expanded print division and the most advanced digital print facility in the southeast United States.
  • XYMOGYM, LLC – our onsite full-service fitness center, which also includes our corporate health and wellness program, XYMOFIT, strongly focusing on the Institute of Functional Medicine’s five pillars of health, which may be offered to outside participants as well.
  • WholeScripts Pharmacy, LLC – our online, truly integrated pharmacy, which opened for business in March 2021, and is the only one that combines exclusive XYMOGEN formulas with prescription medications in convenient daily dose packs. We are currently licensed in 44 states and working aggressively to cover all 50 states.
  • Additionally, PharmacuetiX, our Medical Foods division, as well as the Private Label and International programs are all expected to grow substantially because of our technology and infrastructure enhancements.

An updated quarterly PPM is now available with our latest financial results. The initiatives mentioned above are just a few of the many that we expect will substantially contribute to revenues over the next several quarters.

For fiscal year 2022, XYMOGEN’s Finance Team is forecasting ranges for our revenue, EBITDA and share price that will be dependent on the implementation timing for each of our initiatives. We are projecting revenue to grow 4%-8% equating to $133-$138 million with an EBITDA of $9-$11 million. We are also forecasting that the share price will increase another 2%-5% to $180-$185 by year-end. The share price ended Q2 2022 at $176.94. The forecast will be updated monthly with the revised estimates included in the quarterly Investor Newsletter and on the website.

Per covenants with Bank of America relating to our current $17.6 million of building and equipment financing, the CLA CPA Team completed the full 2021 audit on April 28, 2022, and a copy is now available to investors upon request.



Investors who would like to request a detailed report of their current XYMOGEN stock holdings, a copy of XYMOGEN's most current audited financial statements and/or Private Placement Memorandum (PPM) may email


Investing in XYMOGEN

Should you wish to consider an investment, please email to request information.

Disclosure:This information contains forward-looking statements, including those related to revenue, non-operating expenses, tax rates, earnings, and our ability to continue to align our business to successfully respond to opportunities and changes in our industry. The financial information set forth herein reflects estimates based on information available at this time.

Management Team

Brian Blackburn

Brian Blackburn

CEO, Founder of XYMOGEN

As CEO of XYMOGEN, Brian guides the company's growth and success in close cooperation with executive management and the board of directors. He began his career in the physician based, nutritional sciences industry more than 25 years ago, focusing primarily in the areas of research & development and natural ingredient sourcing. In 2003 he researched, developed and launched the XYMOGEN line of professional formulas. Prior to launching XYMOGEN, Brian was president of the most successful independent distributorship for the largest company in the practitioner-based nutrition market. Building on his background in biochemistry and post-graduate education, Brian has developed functional medicine continuing education programs that have been presented extensively to thousands of physicians across the U.S. since 1995. He received his bachelor of science in biochemistry from John Carroll University.

Stephanie Blackburn

Stephanie Blackburn

Chief Operating Officer

As Chief Operations Officer, Stephanie is responsible for overseeing the management of all of XYMOGEN’s operational areas, including manufacturing, inventory, fulfillment, finance, human resources, marketing, and customer service. She attended the University of Maryland; after which, she began her career in health care operations by ensuring the personnel and budget needs of some of the nation’s top medical research institutions were met. In 1990, Stephanie and Brian moved to Florida to begin a two-person distributorship out of their garage, which eventually grew into a major nutraceutical manufacturer that now employs more than 350 employees. For more than 25 years, Stephanie’s role within the company has remained very hands-on, and she still oversees all personnel decisions, personally signs every check, and actively works to instill XYMOGEN’s core values and culture in all employees.

Mike Mahoney

Mike Mahoney

Senior Vice President

Mike oversees the development and execution of XYMOGEN®'s Sales and Strategic Marketing initiatives and works closely with the company's well tenured consultant sales team. Mike brings a wealth of industry knowledge that encompasses 20 years of experience in the fields of nutrition and natural medicine. He has cultivated relationships at high levels in a large number of medical offices, hospitals and institutions across the country. His contacts and highly regarded reputation in the industry are well known as he is a sought after speaker and consultant. He received academic and athletic scholarships to Fort Hays State University where he received his Bachelor of Science degree in Exercise Physiology.

Daniel Gulick

Daniel Gulick

Vice President, Custom Manufacturing

Daniel Gulick has 19 years of experience working in manufacturing and cGMP compliance. He oversees the critical steps involved in the manufacture of nutraceuticals to assure their stability and efficacy. Daniel earned a Bachelor of Science degree in biology from Arizona State University in 1993. He continues to provide expert judgment to ensure the safety and quality of all formulas manufactured at our facility.

Global Headquarters
Contact Us


NSF Certified
© 2022 XYMOGEN®. All right reserved.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.